Back to Journals » Research Reports in Clinical Cardiology » Volume 6
Review
![Noteworthy comment: The new anti-PCSK9 monoclonal antibodies, with profound abilities to lower LDL-C as well as lipoprotein (a), may be on the verge of ushering in a new era in cardiovascular risk management. This review contains much information about this new class of drugs, and is highly recommended.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Potential of PCSK9 as a new target for the management of LDL cholesterol
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
13,880 | Dovepress* | 13,880+ | 1,380 | 15,260 | |
Totals | 13,880 | 1,380 | 15,260 | ||
*Since 15 July 2015 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
2 | 0 | 0 | 0 | 1 | 1 |
View citations on Google Scholar